Form 4: Passage Bio Director Dolan Sondhi Granted Significant Stock Options

Passage Bio, Inc. director Dolan Sondhi was granted 201,857 stock options with an exercise price of $0.3598, vesting on the earlier of the one-year anniversary of the grant or the 2026 Annual Meeting.

Summary

• Dolan Sondhi, a Director of Passage BIO, Inc. (PASG), was granted 201,857 stock options.
• The stock options have an exercise price of $0.3598 per share.
• The grant date for these options was May 28, 2025.
• The options are set to expire on May 28, 2035.
• The options will vest in full on the earlier of May 28, 2026 (the one-year anniversary of the grant date) or the date of the issuer's 2026 Annual Meeting of stockholders, subject to Mr. Sondhi's continuous service to the issuer.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a standard governance action that aligns interests and aids retention, which is generally positive, though it carries a minor potential for future dilution. Overall, it's a neutral to slightly positive event.

Positives

• The grant of stock options to a director helps align their financial interests with those of the company's shareholders, incentivizing long-term value creation.
• This equity grant serves as a retention mechanism for a key board member, contributing to board stability and continuity.

Negatives

• The issuance of new stock options introduces potential future dilution for existing shareholders if and when these options are exercised.

Risks

• Potential future dilution of existing shareholder equity upon the exercise of the granted stock options.
• The value realized from these options by the director is contingent on the future performance of Passage Bio's stock price, introducing market risk.

Future Outlook

The stock options granted to Director Dolan Sondhi are subject to future vesting conditions, which will occur on the earlier of May 28, 2026, or the date of the issuer's 2026 Annual Meeting, provided continuous service. The options have a long-term expiration date of May 28, 2035, allowing for future potential exercise.

Industry Context

The granting of stock options to directors is a common and widely accepted compensation practice across various industries, particularly in growth-oriented sectors like biotechnology. This practice aims to attract and retain qualified board members by aligning their financial incentives with the long-term performance and shareholder value of the company.

Comparison to Industry Standards

• Granting stock options to directors is a standard component of executive and board compensation packages in publicly traded companies, especially within the biotechnology sector, to foster alignment with shareholder interests.
• The specific volume of options and the exercise price would typically be benchmarked against compensation practices at peer companies of similar market capitalization, stage of development, and industry focus, though this document does not provide such comparative data.

Corporate Governance

Related Party Transactions

• The grant of 201,857 stock options to Dolan Sondhi, a director of Passage BIO, Inc., constitutes a related party transaction as it involves compensation provided to a member of the company's board of directors.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from enhanced director alignment with long-term company performance and retention.
• Employees: No direct impact mentioned, but reflects standard executive compensation practices within the company.
• Management: The Power of Attorney simplifies regulatory compliance for the director, reducing administrative burden.

Next Steps

• The granted stock options will vest on the earlier of May 28, 2026, or the date of the 2026 Annual Meeting, contingent on continuous service.
• Director Dolan Sondhi may choose to exercise these vested options at any time before their expiration date of May 28, 2035.

Key Dates

Recommendation

Keywords

Passage Bio, PASG, Dolan Sondhi, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Biotechnology